NOT-AI-21-003: Notice of Change: Correction of Eligibility Information for RFA-AI-20-056 Coccidioidomycosis Collaborative Research Centers (U19 Clinical Trial Not Allowed)

Notice of Change: Correction of Eligibility Information for RFA-AI-20-056 Coccidioidomycosis Collaborative Research Centers (U19 Clinical Trial Not Allowed)

Notice Number:

NOT-AI-21-003

Key Dates

Release Date:

November 12, 2020

Related Announcements

RFA-AI-20-056 - Coccidioidomycosis Collaborative Research Centers (U19 Clinical Trial Not Allowed)

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

This Notice is being provided as a correction to Section III. Eligibility Information section of RFA-AI-20-056, Coccidioidomycosis Collaborative Research Centers (U19 Clinical Trial Not Allowed), published in the NIH Guide on October 8, 2020. NIAID will allow eligible institutions to submit only one application in response to this Funding Opportunity Announcement.

Currently reads:

3. Additional Information on Eligibility

Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:

A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101).

Revised to read (changes shown in italics below):

3. Additional Information on Eligibility

Number of Applications

Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed.

The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:

A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101).

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Dona Love, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-695-7097
Email: dona.love@nih.gov